Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ima Evaluations LLC Dba Ima Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$22,222,949

874 payments

Through program year 2025, Ima Evaluations LLC Dba Ima Clinical Research is reported as receiving $22,222,949 in research payments, across 874 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $10,700,417 677
2024 Research $4,892,396 152
2023 Research $6,630,135 45

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eli Lilly and Company $14,464,346 128 payments
  2. Moderna TX, Inc. $4,120,735 456 payments
  3. Pfizer Inc. $3,201,288 166 payments
  4. BioXcel Therapeutics, Inc. $214,915 12 payments
  5. AbbVie, Inc. $70,813 19 payments
  6. GlaxoSmithKline, LLC. $60,129 45 payments
  7. Indivior Inc. $46,725 17 payments
  8. Ionis Pharmaceuticals, Inc. $39,725 30 payments
  9. Braintree Laboratories, Inc. $4,273 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $4,964,101 5 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $3,124,516 23 payments
  3. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $2,739,709 209 payments
  4. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $1,330,538 43 payments
  5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,318,409 202 payments
  6. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $980,309 4 payments
  7. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $896,063 8 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $822,679 11 payments
  9. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $765,632 7 payments
  10. A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $695,963 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record